SLC5A2 and metabolic disease: Additionally, we elucidated the specific mechanism by which SGLT2 inhibitors reduce the nuclear translocation of NF-κB and inhibit the expression of inflammatory cytokines, thereby establishing a direct link between SGLT2 inhibition and hypothalamic inflammation in metabolic diseases.